The new 3,000-square-foot laboratory in Oss, expected to be operational in the first quarter of 2025, will provide advanced analytical testing services for both small and large molecules, employing liquid chromatography-mass spectrometry (LC-MS/MS) and fluorometric detection assays, together with the Gyrolab automated technology platform. In Assen, Ardena will expand its capabilities in immunochemistry, flow cytometry, and qPCR platforms, increasing its LC-MS/MS capacity, and adding new Hamilton automated systems.

The addition of the new Oss laboratory will complement Ardena’s current bioanalytical operations in Assen, providing greater flexibility in project timelines and faster turnaround times, the company said. “This expansion allows us to quickly scale our operations, leverage an additional pool of talented professionals, and bring enhanced efficiency and value to our clients, from discovery to late-stage clinical phases,” commented Jeremie Trochu, CEO of Ardena.

According to Ardena, the expanded services can serve a broad spectrum of clients, from small biotech innovators to large pharmaceutical companies, through each phase of drug development, and across a broad range of modalities, including small molecules, therapeutic peptides and proteins, antibodies, antibody-drug conjugates, nanoparticles, oligonucleotides, mRNA, and cell and gene therapies.

The investments in the Netherlands come on the heels of Ardena’s recent announcement to acquire an advanced drug product manufacturing facility in the US from Catalent. “Together, these investments demonstrate Ardena’s focus on growth and innovation, reinforcing our strategy to assist clients navigate through an ever-increasing complex drug development process and bring life-changing therapies to patients worldwide faster,” said Trochu.